Press Release Archive
-
Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results2014 Fourth-Quarter Sales of $18.3 Billion Decreased 0.6%; EPS was $0.89 2014 Full-Year Sales of $74.3 Billion Increased 4.2%; Full-Year EPS was $5.70 Excluding Special Items, 2014 Fourth-Quarter ...
-
FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the Treatment of Schizophrenia
-
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines InitiativeConsortia funded through the IMI Ebola+ Programme Supported by the European Commission Brings together London School of Hygiene and Tropical Medicine, Inserm, University of Oxford, Le Centre Muraz, ...
-
Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO®Findings Add to Rigorous Post-Marketing Safety Program for XARELTO® in Routine Clinical Practice
-
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine RegimenCompany Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2015
-
Johnson & Johnson to Host Fourth-Quarter/ Full-Year 2014 Investor Conference Call on Results
-
Johnson & Johnson Announces Collaboration between Janssen and USAID to Expand Access to Anti-Multidrug-Resistant Tuberculosis (MDR-TB) CompoundMemorandum of Understanding Signed to Address the Global Health Threat of Antibiotic-Resistant Bacteria
-
New National Survey Reveals The Surprising Overall Life Impact Of Joint Pain – It’s More Than PhysicalSurvey at MoreThanJointPain.com Helps Sufferers Better Understand Personal Impact of Joint Pain
-
IMBRUVICA® (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic MutationIMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months